Table 3 Hazard ratios for coronary heart disease (CHD) among cancer survivors according to prediagnosis body mass index (BMI) stratified by first site of cancer at enrollment.

	Prediagnosis BMI (kg/m²)
	< 18.5	18.5–22.9	23.0–24.9	≥ 25.0
Lung cancer survivors (N = 2127)
No. of CHD cases	6	16	10	16
Multivariable-adjusted HR (95% CI)^a	3.08 (1.16–8.15)*	1 (reference)	1.13 (0.49–2.61)	1.68 (0.78–3.62)
Stomach cancer survivors (N = 3363)
No. of CHD cases	8	26	35	32
Multivariable-adjusted HR (95% CI)^a	2.99 (1.31–6.80)**	1 (reference)	1.87 (1.07–3.28)*	1.42 (0.80–2.52)
Colorectal cancer survivors (N = 2412)
No. of CHD cases	2	32	26	28
Multivariable-adjusted HR (95% CI)^a	NC	1 (reference)	1.01 (0.57–1.80)	0.83 (0.47–1.48)
Liver cancer survivors (N = 2001)
No. of CHD cases	1	12	8	9
aHR (95% CI)^a	NC	1 (reference)	1.14 (0.43–3.00)	1.01 (0.39–2.62)
Other types (N = 4704)
No. of CHD cases	4	27	41	51
Multivariable-adjusted HR (95% CI)^a	NC	1 (reference)	2.21 (1.33–3.68)**	2.07 (1.23–3.47)**

Data above are presented in numbers, HR, and HR (95% CI).
HR hazard ratio, CI confidence interval, NSAIDs non-steroidal anti-inflammatory-drugs, NC not calculable.
^aAdjusted for socioeconomic factors (age, sex, residential area, insurance premium), lifestyle (smoking status, alcohol consumption, and physical activity), medical characteristics (fasting serum glucose, total cholesterol, blood pressure, and Charlson comorbidity index), family history (cardiovascular disease), depression, and medication use (aspirin, statin, anti-hypertensive drugs, anti-diabetic drugs, and NSAIDs).
*p < 0.05, **p < 0.01, ***p < 0.001.

Quick links

Search